Table 1.
Patient and clinical characteristics of patients with metastatic cutaneous melanoma receiving ICIs
| Patients and clinical characteristics | ICIs-R (n=15) | ICIs-NR (n=9) | P value |
| Median age at treatment start (years) | 72±15.81 | 70±12.28 | 0.440 |
| Females, n (%) | 9 (60.00) | 2 (22.22) | 0.105 |
| Males, n (%) | 6 (40.00) | 7 (77.78) | |
| Baseline M-stage, n (%) | |||
| M1a | 1 (6.67) | 0 | 1 |
| M1b | 4 (26.67) | 2 (22.22) | |
| M1c-d | 10 (66.67) | 7 (77.78) | |
| Baseline LDH | |||
| Median (μkat/L) | 3.95±1.11 | 3.90±7.36 | 0.850 |
| ≤ULN, n (%) | 8 (53.33) | 4 (44.44) | 0.680 |
| >ULN, n (%) | 6 (40.00) | 5 (55.56) | |
| Missing data, n (%) | 1 (6.67) | 0 | |
| First-line therapy, n (%) | |||
| Anti-PD-1 | 10 (66.67) | 6 (66.67) | 0.551 |
| Anti-CTLA-4 | 3 (20.00) | 3 (33.33) | |
| Anti-PD-1 and anti-CTLA-4 | 2 (13.33) | 0 | |
| Best treatment response, n (%) | |||
| Complete response | 5 (33.33) | 0 | n.a |
| Partial response | 4 (26.67) | 0 | |
| Stable disease | 6 (40.00) | 0 | |
| Progressive disease (no response) | 0 | 9 (100.00) | |
| Progression-free survival, median (days) | 430±375.20 | 73±37.15 | <0.001 |
| Overall survival, median (days) | 809±269.12 | 125±305.24 | <0.001 |
P-values are obtained with t, Wilcoxon, Fisher, or log-rank test, number after ± is SD.
ICIs-NR, patients treated with immune checkpoint inhibitors with no response to treatment; ICIs-R, patients treated with immune checkpoint inhibitors with response to treatment; n.a., not applicable.